Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Federal Home Loan Bank of Cincinnati
Other material
confidence 65%
filed 2026-05-21
Item 2.03
This Item 2.03 disclosure reports the issuance of Consolidated Bonds ($19.5M and $15.5M par amounts) by the Federal Home Loan Bank of Cincinnati on trade dates 5/19/2026. While Item 2.03 is technically designated for "Creation of a Direct Financial Obligation," the filing itself explicitly states "although Consolidated Obligations issuance is material to the FHLB, we have not made a judgment as to the materiality of any particular Consolidated Obligation or Obligations." The disclosure does not fit cleanly into the covenant_breach taxonomy (no breach alleged) and represents routine debt issuance rather than a discrete material event like M&A, impairment, or executive change. The materiality assertion combined with the routine nature of debt issuance for a Federal Home Loan Bank suggests classification as other_material rather than a more specific event type.
View raw filing on EDGAR →
Federal Home Loan Bank of Topeka
Other material
confidence 65%
filed 2026-05-21
Item 2.03
This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) totaling approximately $890 million across eight separate securities issued on trade dates 05/18/2026 and 05/19/2026. While Item 2.03 is the designated item for direct financial obligations, the taxonomy lacks a specific "debt_issuance" category. The disclosure is material to investors as it represents significant new debt obligations for the FHLBank, though the filing itself notes the FHLBank has not made a materiality judgment on individual obligations. This is classified as "other_material" rather than a more specific event type because debt issuance activity, while routine for a Federal Home Loan Bank, does not fit cleanly into the provided taxonomy categories.
View raw filing on EDGAR →
Federal Home Loan Bank of Des Moines
Other material
confidence 65%
filed 2026-05-21
Item 2.03
This Item 2.03 disclosure describes the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Des Moines. While the filing creates direct financial obligations through debt issuance, the prose is primarily explanatory and regulatory in nature, describing the general framework and mechanics of consolidated obligations rather than disclosing a specific new obligation event. The filing explicitly states "we have not made a judgment as to the materiality of any particular consolidated obligation or obligations," suggesting this is a routine periodic disclosure of debt issuance activity rather than a discrete material event. This does not fit cleanly into the more specific event types (covenant_breach, going_concern, etc.) and is best classified as other_material given the inherent materiality of debt issuance to a financial institution.
View raw filing on EDGAR →
Federal Home Loan Bank of San Francisco
Other material
confidence 65%
filed 2026-05-21
Item 2.03
This Item 2.03 disclosure reports the issuance of $15 million in consolidated obligation bonds (CUSIP 3130BAU47, maturing 5/27/2031, 4.875% coupon) by the Federal Home Loan Bank of San Francisco on trade date 5/19/2026. While Item 2.03 is nominally about "creation of a direct financial obligation," the filing itself states that "consolidated obligations issuance is material to the Bank" and the Bank has not made materiality judgments on particular obligations. This is a routine debt issuance disclosure for a government-sponsored enterprise (FHLB), not a covenant breach, going-concern issue, or other acute financial stress signal. The event is material to investors as it affects the Bank's capital structure and leverage, but does not fit neatly into more specific event categories (e.g., it is not a breach, impairment, or M&A activity), warranting classification as other_material.
View raw filing on EDGAR →
WhiteFiber, Inc.
Other material
confidence 72%
filed 2026-05-21
Item 7.01
WhiteFiber announced entry into a five-year, $160+ million AI compute infrastructure contract with an investment-grade technology customer in France, including secured data center capacity and binding project-level financing expected to close in June 2026. While this represents a material commercial development that would affect a reasonable investor's assessment of the company's growth prospects and revenue pipeline, it does not fit cleanly into the standard M&A taxonomy (no acquisition, merger, or change of control) and is disclosed under Item 7.01 (Regulation FD Disclosure) rather than the dedicated Item 1.01 for material agreements. The contract's materiality—representing substantial contracted revenue and strategic positioning in AI infrastructure—warrants classification as a material event, but the absence of a more specific category makes "other_material" the most appropriate choice.
View raw filing on EDGAR →
CO2 Energy Transition Corp.
Other material
confidence 65%
filed 2026-05-21
Item 7.01
The disclosure indicates ongoing progress toward a Business Combination, which is a material M&A-related event for a SPAC. However, the language is vague and forward-looking ("hopes to be in a position to disclose more details in the near future") rather than announcing a definitive agreement or completion. This falls outside the more specific M&A categories (which typically require entry, completion, or termination of a transaction) and is best classified as other_material given its significance to investors in a blank-check company context.
View raw filing on EDGAR →
Falcon's Beyond Global, Inc.
Other material
confidence 72%
filed 2026-05-21
Item 8.01
The disclosure announces that the Company's 11% Series B Cumulative Convertible Preferred Stock commenced trading on Nasdaq Global Market under symbol "FBYDP" on May 21, 2026. While this represents a significant capital structure event and public market listing of a security class, it does not fit cleanly into the standard taxonomy categories (not a dilutive issuance of common equity, not M&A activity, not a routine administrative matter). The event is material to investors as it affects the Company's capital structure and introduces a new publicly-traded security class.
View raw filing on EDGAR →
Patriot Acquisition Corp./CI
Other material
confidence 75%
filed 2026-05-21
Item 8.01
This disclosure describes the completion of a SPAC IPO and related capital-raising activities, including the initial IPO of 16 million units generating $160 million in gross proceeds, private placement of 5.2 million warrants, and subsequent exercise of the underwriter's over-allotment option for 1.5 million additional units generating $15 million. While the IPO itself is a material capital event, it does not fit cleanly into the "earnings_release" category (which typically applies to periodic financial results) or "dilutive_issuance" (which focuses on unregistered equity sales to raise cash in distressed contexts). The disclosure is primarily a post-closing announcement of a completed IPO and related warrant issuances, which is material to investors but lacks a more specific event-type match.
View raw filing on EDGAR →
Hoth Therapeutics, Inc.
Other material
confidence 75%
filed 2026-05-21
Item 8.01
The company announced a material name change from "Hoth Therapeutics, Inc." to "Rocket One, Inc." coupled with a stated intent to restructure and pivot its business focus from therapeutics to artificial intelligence infrastructure, semiconductors, and ultra-low-power AI computing. This represents a fundamental strategic shift that would affect a reasonable investor's assessment of the registrant's business direction and risk profile, though the disclosure does not fit neatly into more specific event categories such as M&A activity, going concern, or material impairment.
View raw filing on EDGAR →
Palmer Square Capital BDC Inc.
Other material
confidence 72%
filed 2026-05-21
Item 8.01
The disclosure announces board approval of an increase and extension of the Company's stock repurchase program. While share repurchase programs can signal management confidence in valuation and affect capital allocation, this announcement does not fit cleanly into the more specific event categories (it is not an earnings release, executive change, M&A activity, impairment, or other defined material event). The materiality to investors lies in the capital allocation decision and potential impact on share count and EPS, warranting classification as other_material.
View raw filing on EDGAR →
Blackstone Secured Lending Fund
Other material
confidence 75%
filed 2026-05-21
Item 8.01
Blackstone Secured Lending Fund disclosed the issuance and closing of $650 million in aggregate principal amount of 5.900% notes due 2031 on May 21, 2026, pursuant to an Eleventh Supplemental Indenture. While this is a material debt issuance that would affect a reasonable investor's assessment of the Fund's capital structure and financial obligations, it does not fit neatly into the more specific event categories (e.g., it is not a restatement, covenant breach, or going-concern disclosure). The disclosure focuses on the terms, covenants, and mechanics of the debt offering rather than a discrete triggering event like a breach or impairment.
View raw filing on EDGAR →
Amanat Acquisition Corp.
Other material
confidence 65%
filed 2026-05-21
Item 1.01
This disclosure describes Amanat Acquisition Corp.'s consummation of an IPO on May 18, 2026, generating $75 million in gross proceeds from 7.5 million Class A shares at $10 per share, along with entry into multiple ancillary agreements (underwriting, trust, registration rights, private placement, and indemnification agreements). While the IPO itself is a material capital-raising event, it does not fit cleanly into the standard 8-K taxonomy—it is neither an earnings release, M&A activity, nor a traditional "material definitive agreement" in the sense of a business transaction. The event is material to investors but lacks a dedicated category, warranting classification as other_material.
View raw filing on EDGAR →
Amanat Acquisition Corp.
Other material
confidence 45%
filed 2026-05-21
Item 5.03
The filing discloses an amendment to the Company's articles of incorporation (Amended Charter filed with the Cayman Islands General Registry on May 18, 2026) in connection with the IPO. While Item 5.03 is a standard disclosure vehicle for charter amendments, the materiality here turns on whether this is a routine administrative filing or a substantive governance change. The reference to IPO context and incorporation of terms "set forth in the Registration Statement on pages 151 to 153" suggests this may be a material governance restructuring tied to going public, but the 8-K excerpt itself provides no detail on what changed or why it matters to investors. Without visibility into the actual charter terms, confidence is moderate; this could be either a routine IPO-related formality or a material governance event.
View raw filing on EDGAR →
Amanat Acquisition Corp.
Other material
confidence 65%
filed 2026-05-21
Item 8.01
This disclosure describes the mechanics of a SPAC's IPO trust account structure and the conditions governing release of $75 million in proceeds. While the IPO itself is a material capital-raising event, the filing does not present it as an earnings release or discrete M&A activity, but rather as a disclosure of trust account governance and redemption mechanics under Item 8.01 (Other Events). The most accurate classification is other_material, as it describes a material financing event that does not fit neatly into the more specific categories.
View raw filing on EDGAR →
KPET Ultra Paceline Corp
Other material
confidence 65%
filed 2026-05-21
The filing discloses that unit holders may elect to separately trade Class A ordinary shares and warrants commencing May 21, 2026, with separated securities trading under distinct NYSE symbols (KPET and KPET.WS). This is a structural change affecting the trading and composition of the company's securities, which would materially affect investor options and the total mix of information available. However, it does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A, impairment, or other defined event type), warranting classification as other_material.
View raw filing on EDGAR →
Twenty One Capital, Inc.
Other material
confidence 72%
filed 2026-05-21
Item 5.03
The filing discloses amendments to the Company's Certificate of Formation and Bylaws that remove references to SoftBank and a Governance Agreement (terminated May 19, 2026), and add an election under Texas Business Organizations Code Section 21.419. While Item 5.03 covers articles and bylaw amendments, the material substance here is the termination of a governance arrangement with significant parties (Tether Investments, SoftBank, and Bitfinex), which represents a material change in control or governance structure rather than routine administrative housekeeping. This does not fit cleanly into the specific event taxonomy but is material to investors assessing the Company's governance and stakeholder relationships.
View raw filing on EDGAR →
Whitehawk Therapeutics, Inc.
Other material
confidence 72%
filed 2026-05-21
Item 8.01
The disclosure announces an option agreement with Hangzhou DAC Biotechnology providing access to a linker-payload (CPT113) for up to five additional ADC programs, which expands the Company's pipeline. While this represents a material strategic development for a biotech company's product pipeline, it does not fit cleanly into the more specific event categories (not an M&A transaction, not an earnings release, not an executive change, and not a financial impairment or covenant breach). The pipeline expansion through a licensing/option agreement is material to investors assessing the company's future prospects but is best classified as other_material.
View raw filing on EDGAR →
Olema Pharmaceuticals, Inc.
Other material
confidence 72%
filed 2026-05-21
Item 7.01
The disclosure announces preliminary clinical data from a Phase 1 study of OP-3136, a KAT6 inhibitor. While this is clinical progress for a biopharmaceutical company, it does not fit neatly into the standard taxonomy categories. It is not an earnings release (no financial results), not an exec change, not M&A, and not a restatement or going-concern issue. Clinical trial data announcements are material to investors in biotech companies as they affect pipeline value and investor sentiment, but lack a dedicated event type; therefore "other_material" is most appropriate.
View raw filing on EDGAR →
Olema Pharmaceuticals, Inc.
Other material
confidence 75%
filed 2026-05-21
Item 8.01
The disclosure announces preliminary Phase 1 clinical data for OP-3136, a drug candidate in development, showing favorable safety, tolerability, and early efficacy signals (tumor shrinkage in 13/19 patients, 3 partial responses, no dose-limiting toxicities). While this is material clinical progress for a biopharmaceutical company, it does not fit neatly into the more specific event categories (not an earnings release, M&A activity, impairment, or litigation). The announcement of positive Phase 1 data would affect a reasonable investor's assessment of the company's pipeline and prospects, warranting classification as a material event outside the standard taxonomy.
View raw filing on EDGAR →
Hims & Hers Health, Inc.
Other material
confidence 45%
filed 2026-05-21
Item 2.03
Item 2.03 discloses creation of a direct financial obligation, with the substance incorporated by reference from Item 1.01 ("Indenture and Notes"). Without access to the Item 1.01 content, the specific nature of the obligation cannot be determined—it could be debt issuance (ma_activity if part of a financing transaction), a covenant breach trigger, or another material event. The reference structure prevents confident classification into a more specific category.
View raw filing on EDGAR →
FMC CORP
Other material
confidence 72%
filed 2026-05-21
Item 8.01
FMC announced the pricing of a $1.2 billion offering of Senior Secured Notes due 2031. While this is a material debt issuance that would affect investor assessment of the company's capital structure and financial position, it does not fit cleanly into the taxonomy's more specific categories (ma_activity applies to acquisitions/dispositions/mergers, not debt offerings; dilutive_issuance applies to equity securities). The disclosure is material but best classified as other_material given the debt financing nature.
View raw filing on EDGAR →
EagleRock Land, LLC
Other material
confidence 45%
filed 2026-05-21
Item 1.01
The filing discloses entry into a "Material Definitive Agreement" (Item 1.01) and incorporates by reference information from Item 2.03 regarding a "Joinder Agreement" under "Predecessor Credit Facility." Without access to the Item 2.03 details, the nature of the agreement cannot be precisely determined—it could relate to debt covenant modifications, credit facility amendments, or other financial arrangements. The reference to a "Joinder Agreement" and "Predecessor Credit Facility" suggests a credit-related transaction, but the specific materiality and event classification depend on details not provided in this excerpt.
View raw filing on EDGAR →
EagleRock Land, LLC
Other material
confidence 65%
filed 2026-05-21
Item 2.03
This Item 2.03 discloses the creation of direct financial obligations in connection with EagleRock's IPO closing: assumption of a $263.3 million Predecessor Credit Facility (maturing July 3, 2027) and entry into a new $200 million revolving Credit Facility with JPMorgan Chase. While Item 2.03 is the designated section for debt obligations, the event does not fit cleanly into the taxonomy's more specific categories (covenant_breach, dilutive_issuance, ma_activity). The disclosure is material to investors assessing the company's capital structure and leverage post-IPO, but the primary event is debt assumption and new financing rather than a breach, impairment, or other discrete triggering event.
View raw filing on EDGAR →
Kraft Heinz Co
Other material
confidence 45%
filed 2026-05-21
Item 2.03
Item 2.03 discloses creation of a direct financial obligation through issuance of Notes, incorporating Item 1.01 by reference. Without access to Item 1.01 details, the nature of the obligation cannot be precisely determined—it could represent debt financing, a covenant breach trigger, or another material event. The reference to Note issuance suggests a financing activity, but the specific materiality and event classification depend on the underlying transaction details in Item 1.01.
View raw filing on EDGAR →
Kraft Heinz Co
Other material
confidence 72%
filed 2026-05-21
Item 7.01
Kraft Heinz disclosed early tender results and pricing terms for a $1.1 billion debt tender offer to repurchase its 2046 and 2049 Senior Notes. While this is a material capital management activity affecting the company's debt structure and financial position, it does not fit cleanly into the M&A taxonomy (which focuses on acquisitions, dispositions, and changes of control) nor any other specific event type. The tender offer is a significant refinancing/debt management event material to investors assessing the company's capital strategy and leverage.
View raw filing on EDGAR →
SCHWAB CHARLES CORP
Other material
confidence 75%
filed 2026-05-21
Item 8.01
Charles Schwab issued $2.25 billion in aggregate principal amount of senior notes ($1 billion at 4.744% due 2030 and $1.25 billion at 5.493% due 2037) with net proceeds of approximately $2.236 million. This is a material debt issuance that does not fit the dilutive_issuance category (which applies to equity securities) and is not a covenant breach, restatement, or other more specific event type. The disclosure of a substantial debt offering is material to investors assessing the registrant's capital structure and financial position.
View raw filing on EDGAR →
Alphabet Inc.
Other material
confidence 72%
filed 2026-05-21
Item 8.01
Alphabet closed a ¥576.9 billion (~$3.8 billion USD equivalent) underwritten public offering of Japanese yen-denominated senior notes across seven tranches with maturities from 2029 to 2066. While this is a material debt issuance that would affect investor assessment of the company's capital structure and leverage, it does not fit cleanly into the standard M&A, dilutive equity issuance, or other specific event categories—it is a debt financing activity disclosed under Item 8.01 (Other Events).
View raw filing on EDGAR →
Victory Capital Holdings, Inc.
Other material
confidence 65%
filed 2026-05-21
Item 1.01
Victory Capital entered into a Seventh Amendment to its Credit Agreement on May 18, 2026, refinancing existing term loans with repriced term loans at lower interest rates (SOFR plus 1.75% or alternate base rate plus 0.75%). While this is a material definitive agreement affecting the company's debt structure and financing costs, it does not fit cleanly into the more specific event categories—it is neither a new acquisition (ma_activity), a covenant breach, nor a going-concern disclosure. The refinancing is material to investors as it affects the company's cost of capital and financial obligations, but the taxonomy lacks a dedicated "debt refinancing" category.
View raw filing on EDGAR →
Victory Capital Holdings, Inc.
Other material
confidence 45%
filed 2026-05-21
Item 2.03
Item 2.03 references Item 1.01 (Business Combinations) by incorporation, indicating a material acquisition or merger that creates direct financial obligations. Without the full Item 1.01 text, the specific nature of the transaction cannot be determined—it could be an M&A activity, a debt issuance, or another material obligation. The reference structure suggests a significant transaction, but the event type cannot be confidently assigned without seeing the underlying Item 1.01 disclosure.
View raw filing on EDGAR →
GATX CORP
Other material
confidence 72%
filed 2026-05-21
Item 1.01
GATX Corporation entered into Amendment No. 1 to its Five Year Credit Agreement on May 21, 2026, extending the termination date by one year (to May 21, 2031) and reducing borrowing margins and facility fees. While this is a material amendment to a significant credit facility, it does not fit cleanly into the M&A activity category (which covers acquisitions, dispositions, mergers, or changes of control). The amendment is a refinancing/restructuring of existing debt terms rather than a new material acquisition or disposition, making "other_material" the most appropriate classification for this material but non-categorical event.
View raw filing on EDGAR →
GATX CORP
Other material
confidence 45%
filed 2026-05-21
Item 2.03
Item 2.03 discloses creation of a direct financial obligation via a Credit Agreement and Amendment, which typically signals a material financing event. However, the section provides no substantive details—it merely incorporates Item 1.01 by reference. Without visibility into Item 1.01's content (e.g., whether this is a routine credit facility renewal, a covenant breach triggering acceleration, or a material debt issuance), the specific event type cannot be reliably determined. The disclosure is material to investors as a financial obligation, but the event classification remains ambiguous.
View raw filing on EDGAR →
FLOWERS FOODS INC
Other material
confidence 65%
filed 2026-05-21
Item 8.01
The filing discloses a material reset of the company's dividend policy, reducing the annual rate to $0.50 per share and declaring a quarterly dividend of $0.1250 per share. While dividend declarations are routine for mature companies, a "reset" of the dividend rate suggests a significant policy change that would affect shareholder returns and investor expectations. This does not fit neatly into the more specific event categories (it is not exec compensation, M&A, or a financial restatement), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
Lumen Technologies, Inc.
Other material
confidence 45%
filed 2026-05-21
Item 2.03
Item 2.03 discloses creation of a direct financial obligation, and the section incorporates Item 1.01 by reference. However, the provided text contains only boilerplate language about exhibits and does not specify the nature, amount, or terms of the obligation itself. Without access to Item 1.01 or the referenced exhibits, the specific event type (e.g., debt issuance, covenant breach, or other financing arrangement) cannot be reliably determined. The reference to "Notes" and "Level 3 Financing" suggests a material financing transaction, but the sparse disclosure here warrants a conservative classification.
View raw filing on EDGAR →
Research Alliance Corp III
Other material
confidence 65%
filed 2026-05-21
Item 5.03
The company adopted an Amended and Restated Memorandum and Articles of Association in connection with its IPO on May 19, 2026. While Item 5.03 disclosures are typically routine governance matters, the adoption of new governing documents concurrent with an IPO is material to investors as it establishes the company's post-IPO governance structure and shareholder rights. However, this is a structural/governance event rather than a specific operational or financial event type in the taxonomy, warranting classification as other_material.
View raw filing on EDGAR →
Research Alliance Corp III
Other material
confidence 75%
filed 2026-05-21
Item 8.01
The filing discloses pricing of an IPO announced via press release on May 19, 2026. While IPO pricing is a material capital-raising event affecting the registrant's equity structure and investor base, it does not fit neatly into the standard 8-K taxonomy (not an earnings release, M&A activity, or other predefined category). This is classified as other_material because it represents a significant corporate event that would materially affect a reasonable investor's assessment of the company, but lacks a more specific event type in the taxonomy.
View raw filing on EDGAR →
Orthofix Medical Inc.
Other material
confidence 75%
filed 2026-05-21
Item 7.01
The FDA reclassified non-invasive bone growth stimulators from Class III to Class II, triggering CMS reimbursement changes that reduce Medicare reimbursement by approximately 10% for HCPCS codes E0747, E0748, and E0760. This regulatory action materially impacts Orthofix's financial outlook, forcing the company to lower full-year 2026 net sales guidance to $838–$848 million and adjusted EBITDA to $90–$93 million, and to withdraw its three-year financial targets. While this is a material event affecting investor assessment, it does not fit neatly into the more specific categories (it is neither a restatement, impairment, covenant breach, nor litigation), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
Blackstone Real Estate Income Trust, Inc.
Other material
confidence 72%
filed 2026-05-21
Item 7.01
This Item 7.01 disclosure presents BREIT's Q1 2026 quarterly update, including performance metrics (+2.0% net return), portfolio composition, and strategic positioning. While it contains performance data and forward-looking commentary on real estate markets and BREIT's investment strategy, it does not constitute a formal earnings release (no complete financial statements or standardized earnings metrics), nor does it fit cleanly into other specific event categories. The disclosure is material to investors as it provides substantive updates on fund performance, portfolio allocation, and capital deployment, but the format and content are more consistent with a general investor update than a traditional earnings announcement.
View raw filing on EDGAR →
Beta Bionics, Inc.
Other material
confidence 72%
filed 2026-05-21
Item 7.01
Beta Bionics disclosed updated timeline expectations for commercialization of its lead product candidate, Mint (a patch pump in development), via press release on May 21, 2026. For a development-stage biotech company, material changes to product commercialization timelines are significant to investors assessing the company's path to revenue and capital requirements. This does not fit neatly into the specific event categories (not an earnings release, M&A, impairment, or litigation), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
Beta Bionics, Inc.
Other material
confidence 75%
filed 2026-05-21
Item 8.01
Beta Bionics announced an updated commercialization timeline for its Mint ACE insulin pump, expecting full commercialization by end of Q2 2027 subject to FDA clearance. This is a material product development milestone for a medical device company, but does not fit neatly into the standard 8-K taxonomy (not an earnings release, M&A activity, impairment, or other specific event type). The disclosure would affect investor assessment of the company's near-term revenue prospects and regulatory progress, warranting classification as a material event outside the defined categories.
View raw filing on EDGAR →
INSULET CORP
Other material
confidence 65%
filed 2026-05-21
Item 5.03
The filing discloses an amendment and restatement of Insulet's Bylaws to establish exclusive forum selection provisions for derivative actions, fiduciary duty claims, and Securities Act claims. While bylaw amendments are typically routine administrative matters, forum selection provisions materially affect shareholders' ability to bring litigation and access to courts, which could influence investor assessment of corporate governance and litigation risk. However, this is a standard governance amendment rather than a discrete material event like M&A, restatement, or executive change, warranting classification as other_material rather than a more specific category.
View raw filing on EDGAR →
CarParts.com, Inc.
Other material
confidence 75%
filed 2026-05-21
Item 3.03
The disclosure describes implementation of a 1-for-10 reverse stock split approved by stockholders on May 11, 2026, effective May 25, 2026. While reverse stock splits modify the capital structure and affect all stockholders uniformly, this event does not fit cleanly into the provided taxonomy categories. It is material to investors as it affects share count, trading mechanics, and CUSIP number, but lacks the specific event-type language of earnings, executive changes, M&A, impairments, or other defined categories. "Other_material" is the appropriate classification for this structural capital event.
View raw filing on EDGAR →
Black Diamond Therapeutics, Inc.
Other material
confidence 72%
filed 2026-05-21
Item 7.01
The filing discloses positive Phase 2 clinical trial results for silevertinib in frontline NSCLC patients with EGFR non-classical mutations via press release under Item 7.01 (Regulation FD Disclosure). While this is material clinical development news that would affect investor assessment of the company's pipeline and prospects, it does not fit the earnings_release category (which typically covers financial results) nor any other specific event type in the taxonomy. Clinical trial results are a distinct category of material disclosure for biotech/pharma companies.
View raw filing on EDGAR →
Black Diamond Therapeutics, Inc.
Other material
confidence 75%
filed 2026-05-21
Item 8.01
Black Diamond Therapeutics announced Phase 2 trial results for silevertinib in frontline NSCLC patients with EGFR non-classical mutations, showing a preliminary median progression-free survival of 15.2 months, ORR of 60%, and no new safety signals. While this is a clinical trial result disclosure, it does not fit the "earnings_release" category (which typically refers to financial results) and is material to investors evaluating the company's pipeline and development prospects. This is classified as "other_material" because it represents a significant clinical milestone for a biotech company's lead candidate that would affect investor assessment of the registrant's value and prospects.
View raw filing on EDGAR →
GCI Liberty, Inc.
Other material
confidence 65%
filed 2026-05-21
Item 7.01
The filing discloses a company name change via press release under Item 7.01 (Regulation FD Disclosure). While a name change is a material corporate event that affects investor identification and trading records, the 8-K section provided does not specify the new name or provide substantive details about the change. The disclosure is material to investors but does not fit neatly into the standard taxonomy categories, making "other_material" the most appropriate classification.
View raw filing on EDGAR →
BICYCLE THERAPEUTICS PLC
Other material
confidence 72%
filed 2026-05-21
Item 8.01
The disclosure announces initial clinical trial data (Duravelo-2) for a candidate therapeutic in metastatic urothelial cancer presented at ASCO. For a clinical-stage or development-focused biopharmaceutical company, positive or significant clinical data announcements are material to investors assessing pipeline progress and regulatory prospects. However, this does not fit neatly into the standard taxonomy categories (not earnings, M&A, impairment, litigation, etc.), warranting classification as other_material.
View raw filing on EDGAR →
First National Master Note Trust
Other material
confidence 65%
filed 2026-05-21
Item 8.01
The filing discloses entry into material financing arrangements: an Indenture Supplement dated May 28, 2026 for issuance of "Offered Notes" and a Risk Retention Agreement among First National Bank of Omaha, First National Funding LLC, and First National Master Note Trust. While this involves debt issuance and securitization activity, the Item 8.01 classification and absence of explicit M&A language make it distinct from standard ma_activity. The disclosure of note offerings and related indenture supplements would materially affect investor assessment of the registrant's capital structure and financing activities.
View raw filing on EDGAR →
Adagio Medical Holdings, Inc.
Other material
confidence 85%
filed 2026-05-21
Item 8.01
Adagio Medical submitted a Premarket Approval (PMA) application to the FDA for its vCLAS® Ventricular Ablation System, a significant regulatory milestone for a medical device company. This event is material to investors as FDA approval is a critical path to commercialization and revenue generation, but it does not fit neatly into the more specific event categories (not an earnings release, M&A activity, impairment, litigation, or other defined types). The submission of a major regulatory application represents a material corporate development warranting disclosure under Item 8.01.
View raw filing on EDGAR →
OMEGA HEALTHCARE INVESTORS INC
Other material
confidence 45%
filed 2026-05-21
Item 7.01
The Item 7.01 disclosure references "executive transitions described above" but the actual content of those transitions is not provided in this section. The filing indicates a press release was issued announcing executive transitions (Exhibit 99.1), which typically signals either exec_departure or exec_appointment. However, without access to the substantive details of the transitions themselves, the most defensible classification is other_material, as executive transitions are inherently material but the specific nature (departure vs. appointment vs. compensation change) cannot be determined from this boilerplate disclosure language alone.
View raw filing on EDGAR →
TRAVELERS COMPANIES, INC.
Other material
confidence 72%
filed 2026-05-21
Item 8.01
The Company entered into a new $1.2 billion Five-Year Revolving Credit Agreement on May 15, 2026, replacing a prior $1.0 billion facility. While this represents a material refinancing and increase in available liquidity, it does not fit neatly into the more specific event categories (ma_activity applies to acquisitions/dispositions, not credit facility amendments; covenant_breach applies to violations, not new covenant establishment). The disclosure is material to investors as it affects the Company's financial flexibility and capital structure, but the event is best classified as other_material given the absence of a dedicated taxonomy entry for credit facility amendments or refinancings.
View raw filing on EDGAR →
PERPETUA RESOURCES CORP.
Other material
confidence 75%
filed 2026-05-21
Item 8.01
The disclosure announces EXIM Board approval of a $2.9 billion senior secured long-term loan to support development of the Stibnite Gold Project. While this is a material financing event that would significantly affect investor assessment of the company's capital structure and project funding, it does not fit cleanly into the standard M&A taxonomy categories. The event is neither a traditional acquisition/disposition nor a debt covenant breach or going-concern disclosure, making "other_material" the most appropriate classification for this major project financing approval.
View raw filing on EDGAR →